You are here:
Rosiglitazone: The BfArM and the EMA emphasise restrictions in indications
2010.07.23
Active substance: rosiglitazone
In July 2010 the CHMP at the EMA initiated assessment of new study results on the antidiabetic, rosiglitazone. The BfArM, like the CHMP, is repeating the advice that the long-existing restrictions in rosiglitazone indications should be strictly observed by prescribing physicians.
risk information - full text (available in German only)